Economic evaluation of oral nirmatrelvir/ritonavir versus best supportive care in patients at high risk for progression to severe COVID-19 in Germany: a cost-effectiveness analysis.

Publication date: Jul 25, 2025

AimTo estimate the cost-effectiveness of Nirmatrelvir/ritonavir (NMV/r) versus best supportive care (BSC) in patients at high-risk for progression to severe COVID-19 from a German health payer perspective. MethodsA closed cohort static model of 1,000 COVID-19 patients capturing the short-term (

Concepts Keywords
Economic antiviral drugs
Germany cost-effectiveness analysis
Nirmatrelvir COVID-19
Severe D61
Germany
H51
I18
nirmatrelvir/ritonavir
omicron
SARS-CoV-2

Semantics

Type Source Name
drug DRUGBANK Ritonavir
disease MESH COVID-19
disease MESH Long Covid

Original Article

(Visited 3 times, 1 visits today)